US equities |
MU $942.23 ▼-1.15% NVDA $224.34 ▼-1.83% SPCX $153.76 ▼-1.77% META $745.29 ▼-2.26% AAPL $345.59 ▲+1.27% TSLA $367.39 ▼-2.09% SNDK $1,440.63 ▼-2.81% AMD $584.15 ▼-3.53%
FinancialContent

Ultragenyx Pharmaceutical Inc. - Common Stock (NQ:RARE)

14.85 -0.07 (-0.47%)
Delayed Quote Updated: 10:24 AM EDT, Oct 14, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Ultragenyx Pharmaceutical Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >
News headline image
ULTRAGENYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Rosen Law Firm Urges Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) Stockholders to Contact the Firm for Information About Their Rights
From The Rosen Law Firm, P.A.
Via Business Wire
RARE Stock Slips 3% Today — What’s Up With Ultragenyx’s Gene Therapy For Sanfilippo Syndrome? ↗
Via Stocktwits
News headline image
Investor Notice: Shareholder Rights Law Firm Robbins LLP Informs Investors of the Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit
From Robbins LLP
Via Business Wire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Ultragenyx Pharmaceutical Inc. – RARE
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
From Pomerantz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
From Pomerantz LLP
Via GlobeNewswire
News headline image
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The Great Rebalancing: Thin Holiday Trading and Institutional Pivots Cap a Volatile 2025
As the clock struck midnight to usher in 2026, investors were left reflecting on a final week of 2025 that was anything but festive. While the broader year was a triumph for equity markets—with the S&P... 
Via MarketMinute
Topics Artificial Intelligence Bonds Economy
News headline image
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
From Pomerantz LLP
Via GlobeNewswire
News headline image
Ultragenyx Completes Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa)
If approved, DTX401 will be the first therapy approved to treat the underlying cause of GSDIa 
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Why Ultragenyx Pharmaceutical Stock Is Bouncing Back Today ↗
One analyst sees significant upside for the stock after yesterday's sell-off. 
Via The Motley Fool
News headline image
Ultragenyx Stock Eyes Best Day In 17 Months As Wall Street Shifts Focus To 2026 Pipeline After Bone Disease Trial Miss ↗
The rally reflects renewed investor attention on longer-term pipeline catalysts and regulatory milestones rather than the recent late-stage trial setback. 
Via Stocktwits
News headline image
Why Ultragenyx Pharmaceuticals Stock Is Plummeting Today ↗
A pharmaceutical company's success with a Phase 2 study doesn't guarantee positive results in Phase 3. 
Via The Motley Fool
News headline image
Which stocks are experiencing notable movement on Monday? ↗
Here are the top movers in Monday's session, showcasing the stocks with significant price changes. 
Via Chartmill
News headline image
Biopharma’s Year-End Rollercoaster: Mereo Plummets 90% as BioMarin Seals $4.8 Billion Amicus Deal
The biopharmaceutical sector witnessed a dramatic surge in volatility today, December 29, 2025, as the industry careened toward the end of its strongest year in two decades. In a day defined by extreme... 
Via MarketMinute
Topics ETFs Intellectual Property
News headline image
Keep an eye on the top gainers and losers in Monday's session. ↗
Wondering how the US markets performed in the middle of the day on Monday? Discover the movers and shakers of today's session in our comprehensive analysis. 
Via Chartmill
News headline image
Why Did RARE Stock Plunge Over 41% Today? ↗
Ultragenyx Pharmaceutical announced disappointing results from its Phase 3 studies for the setrusumab (UX143) in the Osteogenesis Imperfecta (OI) program. 
Via Stocktwits
News headline image
Traders are paying attention to the gapping stocks in Monday's session. ↗
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Monday. 
Via Chartmill
News headline image
Ultragenyx Announces Phase 3 Orbit and Cosmic Results for Setrusumab (UX143) in Osteogenesis Imperfecta
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Ultragenyx to Participate in Investor Conferences in December
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
17 18 Next >